Epcoritamab

Extended indication	Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Large B-Cell Lymphoma (LBCL).
Therapeutic value	No estimate possible yet
Registration phase	Registration application pending

Product

Active substance	Epcoritamab
Domain	Hematology
Reason of inclusion	New medicine (specialité)
Main indication	Aggressive non-Hodgkin’s lymphoma
Extended indication	Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Large B-Cell Lymphoma (LBCL).
Manufacturer	Abbvie
Portfolio holder	Abbvie
Route of administration	Subcutaneous
Therapeutical formulation	Injection
Budgetting framework	Intermural (MSZ)

Registration route	Centralised (EMA)
Type of trajectory	Normal trajectory
ATMP	No
Submission date	November 2022
Expected Registration	December 2023
Orphan drug	Yes
Registration phase	Registration application pending

Therapeutic value	No estimate possible yet
References	NCT04628494

There is currently nothing known about the expected patient volume.

There is currently nothing known about the expected cost.

There is currently nothing known about the possible total cost.

There is currently nothing known about off label use.

There is currently nothing known about indication extensions.

There is currently no futher information available.